Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (3): 597-602. doi: 10.19723/j.issn.1671-167X.2020.03.031

Previous Articles     Next Articles

  

  • Received:2018-11-12 Online:2020-06-18 Published:2020-06-30

RICH HTML

   

PDF (PC)

CLC Number: 

  • R730.51

Table 1

Baseline characteristics of patients"

Variable NLR>2.5
(n=18)		 NLR≤2.5
(n=29)		 P
Age/years, x?±s 68.0±11.0 66.3±11.2 0.244
Gender 0.731
Female 9 16
Male 9 13
ECOG-PS 0.529
1 7 14
2 11 15
TNM staging 0.238
Ⅲ 2 5
Ⅳ 16 24
Site of metastasis 0.178
Liver 5 14
Lung 4 5
Peritoneum 6 11
Others 6 10
Disease control 0.026
Stable 14 13
Progressive 4 16
CA-199 0.684
≥12 000 9 13
<12 000 9 16

Figure 1

Overall survival (A) and progression-free survival (B) for the different groups divided by NLR NLR, neutrophil to lymphocyte ratio."

Figure 2

Overall survival (A) and progression free survival (B) for patients who received treatment of DC-CIK divided by NLR, and overall survival (C) and progression free survival (D) for patients who did not receive treatment of DC-CIK divided by NLR NLR, neutrophil to lymphocyte ratio; DC-CIK, dendritic cell/cytokine induced killer."

Table 2

Multivariable Cox proportional hazard regression analysis of patients’ clinical characteristics and survival"

Variables PFS OS
HR (95%CI) P value HR (95%CI) P value
ECOG-PS: 2 1.087 (0.716-1.358) 0.562 0.873 (0.761-1.132) 0.833
TNM staging: Ⅳ 1.003 (0.882-1.132) 0.638 0.944 (0.839-1.241) 0.793
NLR≤2.5 1.725 (1.448-3.103) 0.027 2.104 (1.582-4.372) 0.010
Infusion cycles 1.024 (0.899-1.219) 0.483 0.918 (0.721-1.149) 0.832
DC-CIK combined S-1 0.383 (0.127-0.639) 0.001 0.303 (0.147-0.659) 0.012

Figure 3

Peripheral blood T cell phenotype before and after the first cycle of DC-CIK cell therapy NLR, neutrophil to lymphocyte ratio; DC-CIK, dendritic cell/cytokine induced killer."

[1] Del Chiaro M, Segersvard R, Lohr M, et al. Early detection and prevention of pancreatic cancer: is it really possible today?[J]. World J Gastroenterol, 2014,20(34):12118-12131.
doi: 10.3748/wjg.v20.i34.12118 pmid: 25232247
[2] Yabar CS, Winter JM. Pancreatic cancer: A review[J]. Gas-troenterol Clin North Am, 2016,45(3):429-445.
[3] Zhang Y, Zhang X, Zhang A, et al. Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis[J]. Onco Targets Ther, 2017,10:4173-4192.
[4] Lin M, Liang S, Jiang F, et al. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage Ⅳ breast cancer[J]. Immunol Lett, 2017,183(3):37-43.
[5] Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3):191-197.
pmid: 10765119
[6] Hagihara K, Ikeda M, Maeda S, et al. Effectiveness of irinotecan, S-1, and bevacizumab for rectal cancer with lung and skin metastases after adjuvant chemotherapy[J]. Gan To Kagaku Ryoho, 2016,43(12):2313-2315.
[7] Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013,31(13):1640-1648.
pmid: 23547081
[8] Morizane C, Okusaka T, Furuse J, et al. A phase Ⅱ study of S-1 in gemcitabine-refractory metastatic pancreatic cancer[J]. Cancer Chemother Pharmacol, 2009,63(2):313-319.
doi: 10.1007/s00280-008-0741-7
[9] Jiang N, Qiao G, Wang X-L, et al. Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073.
[10] Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy[J]. Curr Opin Oncol, 2013,25(1):50-51.
pmid: 23150341
[11] Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism[J]. Cancer Res, 2000,60(1):184-190.
[12] He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer[J]. Med Oncol, 2013,30(1):439.
pmid: 23307251
[13] Luo G, Liu C, Cheng H, et al. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors[J]. Oncol Lett, 2017,13(4):2454-2458.
pmid: 28454419
[14] Chen Y, Yan H, Wang Y, et al. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma[J]. Sci Rep, 2017,7(1):753.
pmid: 28392554
[15] Formica V, Morelli C, Ferroni P, et al. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin[J]. Cancer Biomark, 2016,17(3):335-345.
pmid: 27434293
[16] Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788.
pmid: 23359185
[17] 王艺, 王理伟. 胰腺癌患者免疫状态及免疫治疗进展[J]. 肿瘤, 2018,38(6):610-616.
[18] Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application[J]. Hum Vaccin Immunother, 2017,13(6):1-9.
pmid: 28301266
[19] Chen J, Chen Y, Feng F, et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer[J]. J Thorac Dis, 2018,10(12):6711-6721.
pmid: 30746216
[20] Wang Q, Liu Y, Chen Y, et al. CD300LG improves the cytotoxic activity of CIK[J]. Cent Eur J Immunol, 2017,42(2):117-122.
pmid: 28860929
[21] Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J]. Cancer Med, 2014,3(2):406-415.
pmid: 24519894
[22] Li Y, Wang C, Xu M, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer[J]. J Cancer Res Clin Oncol, 2017,143(5):861-871.
doi: 10.1007/s00432-016-2330-1 pmid: 28108815
[23] Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor[J]. Angiogenesis, 2003,6(4):283-287.
doi: 10.1023/B:AGEN.0000029415.62384.ba pmid: 15166496
[24] Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007,18(1-2):171-182.
doi: 10.1016/j.cytogfr.2007.01.015 pmid: 17329145
[25] Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the evelopment and progression of hepatocarcinogenesis[J]. Clin Cancer Res, 2007,13(3):902-911.
doi: 10.1158/1078-0432.CCR-06-2363 pmid: 17289884
[1] Xiao-jing CHENG,Dong JIANG,Lian-hai ZHANG,Jiang-hua WANG,Ya-zhen LI,Jia-hui ZHAI,Bao-qi YAN,Lu-lu ZHANG,Xing-wang XIE,Zi-yu LI,Jia-fu JI. Preclinical study of T cell receptor specifically reactive with KRAS G12V mutation in the treatment of malignant tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 884-895.
[2] Li ZHANG,Ji-fang GONG,Hong-ming PAN,Yu-xian BAI,Tian-shu LIU,Ying CHENG,Ya-chi CHEN,Jia-ying HUANG,Ting-ting XU,Fei-jiao GE,Wan-ling HSU,Jane SHI,Xi-chun HU,Lin SHEN. Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 971-980.
[3] DING Ting-ting,ZENG Chu-xiong,HU Li-na,YU Ming-hua. Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 203-208.
[4] GU Yang-chun,LIU Ying,XIE Chao,CAO Bao-shan. Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 369-375.
[5] LIU Jing-wei, LU Xu, YANG Zhao-min, DENG Li-juan, YANG Lin. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide [J]. Journal of Peking University(Health Sciences), 0, (): 840-846.
[6] LIU Jing-wei, LU Xu, YANG Zhao-min, DENG Li-juan, YANG Lin. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 840-846.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd